New River Pharmaceuticals And Shire Receive Approvable Letter For VYVANSE? (lisdexamfetamine Dimesylate) For The Treatment Of ADHD

New River Pharmaceuticals Inc. (NASDAQ: NRPH) and its collaborative partner Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that the U.S. Food and Drug Administration (FDA) has issued a second approvable letter for VYVANSE (lisdexamfetamine dimesylate, formerly known as NRP104) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). [click link for full article]

More: continued here

Filed under: ADHD on April 5th, 2007